Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®.
Gisle LangsletBernard ZinmanChristoph WannerStefan HantelRosa-Maria EspaderoDavid FitchettOdd Erik JohansenPublished in: Diabetes & vascular disease research (2021)
The beneficial cardiovascular effects of empagliflozin was consistent across higher and lower LDL-cholesterol levels at baseline.
Keyphrases